OncoSec Medical Incorporated (NASDAQ:ONCS) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, October 11th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

OncoSec Medical Incorporated (NASDAQ:ONCS) opened at 1.04 on Monday. The company has a 50-day moving average of $0.98 and a 200-day moving average of $1.08. OncoSec Medical Incorporated has a 52 week low of $0.88 and a 52 week high of $2.08. The company’s market cap is $22.01 million.

ONCS has been the subject of several research reports. HC Wainwright set a $6.00 target price on shares of OncoSec Medical and gave the company a “buy” rating in a report on Monday, June 12th. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a research report on Wednesday, June 14th. Dawson James reissued a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a research report on Thursday, July 6th. ValuEngine raised shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Finally, Maxim Group reissued a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. OncoSec Medical has an average rating of “Buy” and a consensus price target of $5.33.

TRADEMARK VIOLATION WARNING: “OncoSec Medical Incorporated (ONCS) Set to Announce Quarterly Earnings on Wednesday” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/09/oncosec-medical-incorporated-oncs-set-to-announce-quarterly-earnings-on-wednesday.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Earnings History for OncoSec Medical (NASDAQ:ONCS)

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.